Avacopan
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease (ESRD)
Conditions
End-Stage Renal Disease (ESRD)
Trial Timeline
Jul 11, 2024 → Oct 5, 2024
NCT ID
NCT06468826About Avacopan
Avacopan is a phase 1 stage product being developed by Amgen for End-Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT06468826. Target conditions include End-Stage Renal Disease (ESRD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06321601 | Phase 3 | Recruiting |
| NCT06468826 | Phase 1 | Completed |
| NCT03852472 | Phase 2 | Completed |
| NCT06004934 | Phase 1 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease (ESRD)